Unlocking Affordability: Cell Therapy Development Strategies to Expand Patient Access

VHH is a novel modality in antibody based therapy. Its naturally generated single-domain structure makes it an ideal building block in cell therapy. The Carvykti developed by Legend/J&J demonstrated that unique design of CAR domain based on proper affinity, avidity and epitope diversity of VHH candidates is a crucial factor for a successful therapy. Here we are presenting stories of CAR lead discovery through the VHH naïve phage library and camelid immunization phage library under different scenarios. In each of these studies, a panel of antibody candidates with desirable affinity & diversity were obtained for downstream CAR-T development.

The current global market of cell and gene therapies (CGT) is valued over $ 15 billion. This is expected to grow at rate of nearly 20% every year from 2022 to 2032 and reaches over $80 billion within a decade. Both plasmids and viral vectors have emerged as the key players in the field of CGT. Plasmid DNA can serve as DNA drug itself or be used for generating viral vectors. Whereas, viral vectors can serve as vehicles to deliver therapeutic genes to treat monogenic disorders, cancers, and infectious diseases. As such, manufacturing high quality plasmids and viral vectors is a must to guarantee the success of CGT.